The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Journal: Evidence-based Cardiology. 2015;8(4): 18‑25

DOI: 10.17116/dokkardio2015418-25

Read: 1954 times

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

. Evidence-based Cardiology. 2015;8(4):18‑25. (In Russ.)
https://doi.org/10.17116/dokkardio2015418-25

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

Close metadata

References:

  1. WHO. A global brief on hypertension. Geneva: World Health Organization, 2013.
  2. Lewington S., Clarke R., Qizilbash N., et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903—1913.
  3. Lawes C.M.M., Rodgers A., Bennett D.A., et al. Blood pressure and cardiovascular disease in the Asia Pacific region. J Hypertens 2003;21:707—716.
  4. Rapsomaniki E., Timmis A., George J., et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet 2014;383:1899—1911.
  5. Collins R., Peto R., MacMahon S., et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827—838.
  6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255—3264.
  7. Staessen J., Fagard R., Thijs L., et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757—764.
  8. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887—1898.
  9. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829—840. 
  10. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033—1041.
  11. Yusuf S., Sleight P., Pogue J., et al. Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000;342:145—153.
  12. Wright J.T.J., Williamson J.D., Whelton P.K., et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103—2116.
  13. Emdin C., Rahimi K., Neal B., et al. Blood pressure lowering in type 2 diabetes. JAMA 2015;313:603—615. 
  14. James P., Oparil S., Carter B., et al. 2014 Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311:507—520.
  15. Wright J.T. Jr, Fine L.J., Lackland D.T., et al. Evidence supporting a systolic blood pressure goal of less than 150 mm Hg in patients aged 60 years or older: the minority view. Ann Intern Med 2014;160:499—503.
  16. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
  17. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013;34:2159—2219.
  18. NICE. The clinical management of primary hypertension in adults: clinical guideline 127. London: National Institute for Health and Care Excellence, 2011.
  19. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions. PLoS Med 2009;6: e1000100.
  20. World Health Organization — International Society of Hypertension Blood Pressure Lowering Treatment Trialists’ Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998;16:127—137.
  21. Higgins J.P., Green S., eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008: i—xxi.
  22. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217—2226.
  23. Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755—1762.
  24. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851—860.
  25. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985;291:97—104.
  26. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405—412.
  27. Chaturvedi V., Patel A., Chalmers J., et al. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J 2003;24:475—484.
  28. Ruggenenti P., Fassi A., Ilieva A.P., et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351:1941—1951.
  29. Meredith P.A., Östergren J., Anand I., et al. Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program. J Am Coll Cardiol 2008;52:2000—2007.
  30. Rouleau JL, Roecker EB, Tendera M, et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure the carvedilol prospective randomized cumulative survival (COPERNICUS) study. J Am Coll Cardiol 2004;43:1423—1429.
  31. Anand I.S., Tam S.W., Rector T.S., et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the african-american heart failure trial. J Am Coll Cardiol 2007;49:32—39.
  32. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002;288:2421—2431.
  33. Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998;338:645—652.
  34. Schrier R.W., Estacio R.O., Mehler P.S., Hiatt W.R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 2007;3:428—438.
  35. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086—1097.
  36. Asayama K., Ohkubo T., Metoki H., et al. Cardiovascular outcomes in the first trial of antihypertensive therapy guided by self-measured home blood pressure. Hypertens Res 2012;35:1102—1110.
  37. Holman R., Turner R., Stratton I., et al. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713—720.
  38. Turner R., Holman R., Stratton I., et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703—713.
  39. McMurray J., Solomon S., Pieper K., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: An analysis of the valsartan in acute myocardial infarction trial (VALIANT). J Am Coll Cardiol 2006;47:726—733.
  40. Yusuf S., Diener H., Sacco R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225—1237.
  41. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611—616.
  42. Wilhemsen L., Berglund G., Elmfeldt D., et al. Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. J Hypertens 1987;5:561—572.
  43. Kanamasa K., Kimura A., Miyataka M., et al. Incidence of cancer in postmyocardial infarction patients treated with short-acting nifedipine and diltiazem. Cancer 1999;85:1369—1374.
  44. Levine T., Bernink P., Caspi A., et al. Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Circulation 2000;101:758—765.
  45. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999;34:1129—1133.
  46. Ogawa H., Kim-Mitsuyama S., Matsui K., et al. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 2012; 125:981—990.
  47. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980;69:725—732.
  48. Gong L., Zhang W., Zhu Y., et al. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14:1237—1245.
  49. Liu L., Wang J., Gong L., et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998;16:1823—1829.
  50. Wang J.G., Staessen J., Gong L., Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. Arch Intern Med 2000;160:211—220.
  51. Ogihara T., Matsuoka H., Rakugi H. Practitioner’s trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int 2011;11:414—421.
  52. Xie X., Atkins E., Lv J., et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. Lancet 2015; published online Nov 7. http://dx.doi.org/10.1016/S0140-6736(15)00805-3.
  53. Cushman W.C., Evans G.W., Byington R.P., et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575—1585.
  54. Di Angelantonio E., Kaptoge S., Wormser D., et al. Association of cardiometabolic multimorbidity with mortality. JAMA 2015;314:52—60.
  55. Parving H.-H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204—2213.
  56. Neal B., MacMahon S., Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000;356:1955—1964.
  57. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs — overview and meta-analyses. J Hypertens 2015;33:195—211.
  58. Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417—2428.
  59. Sundström J., Arima H., Jackson R., et al. Effects of blood pressure reduction in mild hypertension. Ann Intern Med 2015;162:184—191.
  60. Rahimi K., MacMahon S. Blood pressure management in the 21st century: maximizing gains and minimizing waste. Circulation 2013;128:2283—2285.
  61. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens 2014;32:2285—2295.
  62. Turnbull F., Neal B., Algert C., et al. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527—1535.
  63. Ninomiya T., Perkovic V., Turnbull F., et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ 2013;347:f5680.
  64. Coresh J., Astor B., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1—12.
  65. Chadban S., Briganti E., Kerr P., et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol 2003;14 (7 Suppl 2):S131—138.
  66. Perkovic V., Cass A., Patel A., et al. High prevalence of chronic kidney disease in Thailand. Kidney Int 2008;73:473—479.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.